Bristol-Myers Squibb Company Press Releases

BMY 
$65.64
*  
1.18
1.83%
Get BMY Alerts
*Delayed - data as of Jul. 31, 2015  -  Find a broker to begin trading BMY now
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By

Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab and Opdivo (nivolumab) in Advanced Solid Tumors in the U.S.
7/29/2015 7:00:00 PM - Business Wire
▲1.08 % Price Change since this news event. The Volume Ratio is 0.55.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


European Medicines Agency Validates and Grants Accelerated Assessment of Marketing Authorization Application for Empliciti (elotuzumab) For the Treatment of Multiple Myeloma in Patients Who Have Received One or More Prior Therapies
7/27/2015 7:00:00 AM - Business Wire
▼-1.20 % Price Change since this news event. The Volume Ratio is 1.43.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


FDA Approves Daklinza (daclatasvir) for the Treatment of Patients with Chronic Hepatitis C Genotype 3
7/24/2015 2:06:00 PM - Business Wire
▼-1.43 % Price Change since this news event. The Volume Ratio is 2.03.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Bristol-Myers Squibb Reports Second Quarter Financial Results
7/23/2015 7:30:00 AM - Business Wire
▼-7.55 % Price Change since this news event. The Volume Ratio is 1.91.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




European Medicines Agency Validates Two Parallel Type II Variation Applications to Extend the Opdivo (nivolumab) Indication in Europe
7/23/2015 6:30:00 AM - Business Wire
▼-5.82 % Price Change since this news event. The Volume Ratio is 1.91.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Second-Generation Investigational HIV-1 Maturation Inhibitor Demonstrates Positive New Phase IIa Results, Supporting Continued Development
7/21/2015 2:00:00 PM - Business Wire
▼-5.01 % Price Change since this news event. The Volume Ratio is 1.69.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for Investigational HIV-1 Attachment Inhibitor for Heavily Treatment-Experienced Patients
7/21/2015 9:00:00 AM - Business Wire
▼-6.36 % Price Change since this news event. The Volume Ratio is 1.59.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


European Commission Approves Nivolumab BMS, the First PD-1 Immune Checkpoint Inhibitor in Europe Proven to Extend Survival for Patients with Previously-Treated Advanced Squamous Non-Small Cell Lung Cancer
7/20/2015 12:07:00 PM - Business Wire
▼-6.30 % Price Change since this news event. The Volume Ratio is 1.27.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




CheckMate -025, a Pivotal Phase III Opdivo (nivolumab) Renal Cell Cancer Trial, Stopped Early
7/20/2015 8:00:00 AM - Business Wire
▼-5.35 % Price Change since this news event. The Volume Ratio is 1.32.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Abitibi Royalties "Royalty Search" Update
7/20/2015 8:00:00 AM - Market Wire


European Commission Approves Bristol-Myers Squibb’s Evotaz (atazanavir and cobicistat fixed-dose combination) for the Treatment of HIV-1 Infection in Adults
7/16/2015 9:21:00 AM - Business Wire
▼-5.25 % Price Change since this news event. The Volume Ratio is 0.91.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


MUSC and Bristol-Myers Squibb Announce Translational Research Collaboration Focused on Fibrotic Diseases
7/15/2015 8:30:00 AM - Business Wire
▼-6.23 % Price Change since this news event. The Volume Ratio is 1.11.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day








Bristol-Myers Squibb Expands R&D Presence Within Hubs of World Class Science and Innovation
6/25/2015 9:30:00 AM - Business Wire
▼-2.03 % Price Change since this news event. The Volume Ratio is 1.13.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day






Allied-Bristol Life Sciences Licenses Intellectual Property from Harvard University
6/22/2015 2:00:00 AM - Business Wire
▼-1.75 % Price Change since this news event. The Volume Ratio is 0.78.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab), the First and Only PD-1 Checkpoint Inhibitor Approved in Europe, for Both First-Line and Previously-Treated Advanced Melanoma Patients
6/19/2015 11:37:00 AM - Business Wire
▼-2.12 % Price Change since this news event. The Volume Ratio is 1.79.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Bristol-Myers Squibb to Announce Results for Second Quarter 2015 on July 23
6/18/2015 9:00:00 AM - Business Wire
▼-1.00 % Price Change since this news event. The Volume Ratio is 1.07.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Bristol-Myers Squibb Announces Dividend
6/16/2015 4:30:00 PM - Business Wire
▼-0.32 % Price Change since this news event. The Volume Ratio is 1.14.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


PhRMA Elects New Members of Board of Directors
6/16/2015 10:00:00 AM - PR Newswire